Biotest AG logo

BIO3 - Biotest AG News Story

€29.6 -0.2  -0.7%

Last Trade - 4:36pm

Sector
Healthcare
Size
Mid Cap
Market Cap £1.02bn
Enterprise Value £1.35bn
Revenue £419.7m
Position in Universe 387th / 1046

UPDATE 1-Takeda-led COVID-19 plasma treatment enters clinical trial with first patient

Fri 9th October, 2020 3:21am
(Adds WHO caution on treatment, call for donations in last two
paragraphs)
    TOKYO, Oct 9 (Reuters) - Japan's Takeda Pharmaceutical Co
 4502.T  said on Friday an alliance of drugmakers it spearheads
has enrolled its first patient in a global clinical trial of a
blood plasma treatment for COVID-19 after months of regulatory
delays.
    The phase 3 trial by the group, known as the CoVIg Plasma
Alliance, aims to enroll 500 adult patients from the United
States, Mexico and 16 other countries, according to a statement.
    Patients will be treated with Gilead Science Inc's  GILD.O 
Remdesivir alongside the plasma treatment, which will be
provided by CSL Behring, Takeda and two other companies.
    "We are hopeful that data from the clinical trial will be
available before the end of the year," Bill Mezzanotte, chief
medical officer of CSL Behring, said in the release.
    The group had aimed to begin the clinical trial in July, but
it was delayed pending regulatory approval. The National
Institutes of Health in the U.S. is the trial's sponsor.
 urn:newsml:reuters.com:*:nL4N2GE29X
    The alliance, which also includes Germany's Biotest AG
 BIOG.DE  and Octapharma Plasma, is working on a hyperimmune
globulin therapy derived from blood plasma. It offers a
standardised dose of antibodies and doesn't need to be limited
to patients with matching blood types.  urn:newsml:reuters.com:*:nL3N2F02GB
    The World Health Organization has urged caution about plasma
treatments for COVID-19 saying evidence they work is "low
quality", even as the United States issued emergency
authorisation for such therapies.  urn:newsml:reuters.com:*:nL8N2FQ2VU
    Testing and production of the treatments are also vulnerable
to a scarcity of blood plasma from people who have recovered
from COVID-19. In its release, the CoVIg Plasma Alliance urged
such individuals to consider donating their plasma.

 (Reporting by Rocky Swift; Editing by Kenneth Maxwell and
Christopher Cushing)
 ((rocky.swift@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.